Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ampio, Cyclo, Eledon, Enzyvant, Hillhurst, Instil, Krystal, RDIF, Reata, Revive, Rockwell Medical, Sol-Gel Technologies.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Affiris, Awakn, Clarus, Canbridge, Compugen, Daiichi, DNA Script, Dynavax, Enalare, Epivax, Evotec, Generex, Gilead, Glauconix, Guardant, Inmed, Inveniai, Logicbio, Merck and Co., Moderna, Nascent, Neurocrine, Nicox, Ose, Pyxis, Sarepta, Sentia, Shasqi, Shionogi, Storm, Veloxis, Zogenix.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Aim, Aldeyra, Alkermes, Ampio, Aravive, Brickell, Discgenics, Fosun, Gila, Logicbio, Lumos, Noxopharm, Obseva, Protagonist, Reithera, Revance, Sifi, Verona.

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Brainsway, Lucira Health, Neurolutions, Phoenix Cardiac, Speedx.

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Accessdx, Amydis, Becton Dickinson, Biocardia, Djo Global, Ekso Bionics, Empower Dx, Genetic Technologies, Heartflow, Immucor, Infinity Biologix, Inspire Medical, Japan Lifeline, Jase Health, Mediso Medical Imaging Systems, Medshape, Medtronic, Microbix Biosystems, Multimed, Rs2d, Speedx, Surgical Theater, Transforming Systems, Tytocare, Uber, Vitalhub.

Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Algernon, Amydis, Astrazeneca, Axsome, Chugai, Crispr, Cstone, Glenmark, J&J, Karyopharm, Merck & Co., Neoleukin, Scopus, Tarsier, Uniqure, Vertex, Voyager.

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Advaxis, Asher, Ashvattha, Biontech, BMS, Boston, Bugworks, Carisma, Cybin, Daiichi Sankyo, Evotec, Geneleap, GW, Immunome, Jazz, Johnson & Johnson, Landos, Lantern, Leading, Moderna, OS Therapies, Palisades, Pieris, Probiogen, Psybio, RDIF, Samsung, Sanofi, Seneca, TG, Therapeutic Solutions, Viscoran.

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Acrotech, Amgen, Astrazeneca, Baudax, Biond, Biosplice, Chemomab, Corat, Daré, G1, Hemostemix, I-Mab, Imcheck, J&J, Kintor, Niminus, Obi, Reviva, Sanofi, Sirnaomics, Vertex.

Shares of Inovio Inc. (NASDAQ:INO) fell 25% to $6.85 on April 23 after the company said the U.S. Department of Defense scratched funding for the phase III portion of an ongoing trial of its COVID-19 vaccine candidate, INO-4800, in light of the broad availability of other COVID-19 vaccines in the U.S. The news followed recent phase I data showing '4800 performed about in line with already available competitors against SARS-CoV-2 variants now dominant in the U.S.